<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02910089</url>
  </required_header>
  <id_info>
    <org_study_id>D1843R00254</org_study_id>
    <nct_id>NCT02910089</nct_id>
  </id_info>
  <brief_title>ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus</brief_title>
  <acronym>ENGAGE-DM</acronym>
  <official_title>ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM): A 12-month Study of the Impact of Combined Shared-decision Making and Brief Negotiated Interviewing on Disease Control and Medication Adherence in Patients With Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham Women's Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether a combination of pharmacist-delivered
      patient engagement techniques improves disease control and medication adherence among
      patients with poorly-controlled diabetes compared with usual care. These engagement
      techniques include shared decision-making and brief negotiated interviewing and are delivered
      telephonically.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The US is facing a growing epidemic of type 2 diabetes. Among patients with poorly controlled
      diabetes, it is often not clear whether the problem is attributable to failure to
      appropriately intensify therapy, poor adherence to prescribed medications, unwillingness to
      accept new treatments or a combination of these factors. Multi-component pharmacist-delivered
      interventions, particularly those rooted in patient engagement, have been shown to be some of
      the most effective at improving adherence to chronic disease medications. Even though shared
      decision making and brief negotiated interviewing are complementary patient engagement
      techniques, the effectiveness of combining these 2 intervention approaches, especially in the
      management of diabetes, is unknown.

      In this study of patients using at least one oral hypoglycemic therapy with poorly controlled
      disease, the investigators examine the impact of a shared decision making and behavioral
      interviewing intervention delivered telephonically by pharmacists, compared with usual care.
      Briefly, all patients allocated to the intervention will be mailed a patient decision aid to
      prime them for encounters with pharmacists. After receiving the decision aid, these patients
      will be asked to engage in and provide informed consent for at least 4 telephonic discussions
      with pharmacists about their diabetes treatment options, goals, and preferences, medication
      adherence, strategies for reducing adherence barriers, and the benefits of maintaining blood
      glucose control. The study is being conducted within a large insurer and consists of 700
      patients each allocated to the intervention group and the control group. Analyses will be
      performed on an intent-to-treat basis.

      After study completion, the investigators will also use predictive analytics to examine
      whether treatment response could be predicted based on patient characteristics, such as
      sociodemographic, clinical, medication use, and other motivational characteristics, which
      will provide information about which patients are most likely to benefit from the
      intervention.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2016</start_date>
  <completion_date type="Actual">December 20, 2017</completion_date>
  <primary_completion_date type="Actual">December 20, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated Hemoglobin (HbA1c):</measure>
    <time_frame>baseline and at the end of 12 months post index date</time_frame>
    <description>Pre- to post-intervention change in mean HbA1c levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medication Adherence (PDC Measure)</measure>
    <time_frame>during follow-up period of 12 months post index date</time_frame>
    <description>Mean Adherence (PDC) in each study arm in the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage (Proportion x 100) of Patients Achieving Optimal Adherence</measure>
    <time_frame>during follow-up period of 12 months post index date</time_frame>
    <description>Percentage (Proportion x 100) of patients in each study arm achieving optimal adherence (PDC ≥0.80) in the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients Achieving HbA1c</measure>
    <time_frame>baseline and at the end of 12 months post index date</time_frame>
    <description>Percentage (Proportion x 100) of patients in each study arm achieving optimal HbA1c control in the follow-up period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1400</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Shared Decision Making/Brief Negotiated Interviewing</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Shared Decision Making</intervention_name>
    <description>This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).</description>
    <arm_group_label>Shared Decision Making/Brief Negotiated Interviewing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Commercially-insured beneficiaries

          -  Receive all medical/prescription drug benefits through Horizon

          -  On ≥1 one oral hypoglycemic agent

          -  Latest HbA1c measurement ≥ 8% (within previous 6 months)

          -  Provided phone number to Horizon

        Exclusion:

        - Currently using any insulin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niteesh K. Choudhry, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham Women's Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eric Wittbrodt, PharmD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>2115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4399&amp;filename=D1843R00254_ENGAGE_SAP_RedactedPDFA.pdf</url>
    <description>D1843R00254_ENGAGE_SAP_RedactedPDFA</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4399&amp;filename=D1843R00254_ENGAGE_DM_CSP_redacted_PDFA.pdf</url>
    <description>D1843R00254_ENGAGE_Protocol_redactedPDFA</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4399&amp;filename=D1843R00254_ENGAGE_SAP_redacted.pdf</url>
    <description>D1843R00254_ENGAGE_SAP_RedactedPDFA</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 4, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <results_first_submitted>December 6, 2018</results_first_submitted>
  <results_first_submitted_qc>July 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 29, 2019</results_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 17, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02910089/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02910089/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potentially eligible patients for inclusion in this study were those who: (1) were ≥18 years of age, (2) had filled a prescription for 1 or more oral hypoglycemic agents within the prior 12 months, and (3) had evidence of poor glycemic control (A1C ≥8%) within the previous 6 months.</recruitment_details>
      <pre_assignment_details>Patients were excluded if, prior to identification, they had fewer than 3 months of continuous enrolment in the health plan, had recently filled insulin or had no available telephone contact information.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Shared Decision Making/Brief Negotiated Interviewing</title>
          <description>This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).</description>
        </group>
        <group group_id="P2">
          <title>Control Arm</title>
          <description>Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="700">Patients allocated to intervention</participants>
                <participants group_id="P2" count="700">Patients allocated to control</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="678">22 patients ineligible (3.1%)</participants>
                <participants group_id="P2" count="684">16 Patients ineligible (2.3%)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost insurance eligibility</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Population excludes patients who lost insurance eligibility between the time of data pull and randomization.</population>
      <group_list>
        <group group_id="B1">
          <title>Shared Decision Making/Brief Negotiated Interviewing</title>
          <description>This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).</description>
        </group>
        <group group_id="B2">
          <title>Control Arm</title>
          <description>Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="678"/>
            <count group_id="B2" value="684"/>
            <count group_id="B3" value="1362"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Full Analysis Set</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.0" spread="8.1"/>
                    <measurement group_id="B2" value="54.6" spread="8.4"/>
                    <measurement group_id="B3" value="54.6" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="273"/>
                    <measurement group_id="B3" value="509"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="442"/>
                    <measurement group_id="B2" value="411"/>
                    <measurement group_id="B3" value="853"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="678"/>
                    <measurement group_id="B2" value="684"/>
                    <measurement group_id="B3" value="1362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glycosylated Hemoglobin (HbA1c):</title>
        <description>Pre- to post-intervention change in mean HbA1c levels</description>
        <time_frame>baseline and at the end of 12 months post index date</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Shared Decision Making/Brief Negotiated Interviewing</title>
            <description>This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Hemoglobin (HbA1c):</title>
          <description>Pre- to post-intervention change in mean HbA1c levels</description>
          <population>Full Analysis Set</population>
          <units>Percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="678"/>
                <count group_id="O2" value="684"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="1.96"/>
                    <measurement group_id="O2" value="-0.79" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>As per the SAP, no p-values were computed. Only point estimates with 95% confidence intervals were evaluated.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
            <estimate_desc>Model-based Mean Differences are reported that have been adjusted for imbalanced baseline characteristics</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Adherence (PDC Measure)</title>
        <description>Mean Adherence (PDC) in each study arm in the follow-up period</description>
        <time_frame>during follow-up period of 12 months post index date</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Shared Decision Making/Brief Negotiated Interviewing</title>
            <description>This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Adherence (PDC Measure)</title>
          <description>Mean Adherence (PDC) in each study arm in the follow-up period</description>
          <population>Full Analysis Set</population>
          <units>Percentage of Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="678"/>
                <count group_id="O2" value="684"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5" spread="31.6"/>
                    <measurement group_id="O2" value="66.2" spread="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Average of the percentage (proportion x 100) of days covered across all subjects.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.42</ci_lower_limit>
            <ci_upper_limit>4.40</ci_upper_limit>
            <estimate_desc>Model-based Mean Differences are reported that have been adjusted for imbalanced baseline characteristics</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage (Proportion x 100) of Patients Achieving Optimal Adherence</title>
        <description>Percentage (Proportion x 100) of patients in each study arm achieving optimal adherence (PDC ≥0.80) in the follow-up period</description>
        <time_frame>during follow-up period of 12 months post index date</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Shared Decision Making/Brief Negotiated Interviewing</title>
            <description>This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage (Proportion x 100) of Patients Achieving Optimal Adherence</title>
          <description>Percentage (Proportion x 100) of patients in each study arm achieving optimal adherence (PDC ≥0.80) in the follow-up period</description>
          <population>Full Analysis Set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="678"/>
                <count group_id="O2" value="684"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2"/>
                    <measurement group_id="O2" value="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients Achieving HbA1c</title>
        <description>Percentage (Proportion x 100) of patients in each study arm achieving optimal HbA1c control in the follow-up period</description>
        <time_frame>baseline and at the end of 12 months post index date</time_frame>
        <population>Full Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Shared Decision Making/Brief Negotiated Interviewing</title>
            <description>This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.</description>
          </group>
        </group_list>
        <measure>
          <title>Patients Achieving HbA1c</title>
          <description>Percentage (Proportion x 100) of patients in each study arm achieving optimal HbA1c control in the follow-up period</description>
          <population>Full Analysis Set</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="678"/>
                <count group_id="O2" value="684"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.8"/>
                    <measurement group_id="O2" value="38.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>As per the SAP, no p-values were computed. Only point estimates with 95% confidence intervals were evaluated.</non_inferiority_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. In clinical studies, an AE can include an undesirable medical condition occurring at any time, including run-in or washout periods, even if no study treatment has been administered.</desc>
      <group_list>
        <group group_id="E1">
          <title>Shared Decision Making/Brief Negotiated Interviewing</title>
          <description>This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).</description>
        </group>
        <group group_id="E2">
          <title>Control Arm</title>
          <description>Seven hundred patients will also be identified by Horizon Analytics as a control group for analyses purposes only; these patients will not be contacted.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="678"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="684"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="678"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="684"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="684"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="684"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="684"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="684"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="684"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="684"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="678"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="684"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Evaluation of glycemic control is limited to participants who had baseline labs available. ~29% had missing outcomes data for the primary outcome; while we used multiple imputation to evaluate the study, this could have influenced the findings.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Susan Thomas, MD</name_or_title>
      <organization>Astrazeneca Pharmaceuticals</organization>
      <phone>302-886-5589</phone>
      <email>Susan.Thomas2@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

